Cargando…
Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
Polycythemia vera (PV) is a burdensome, chronic myeloproliferative neoplasm characterized by activating mutations in Janus kinase 2, erythrocytosis, and bone marrow hypercellularity. The goals of treatment are to achieve hematocrit and blood count control to ultimately reduce the risk of thrombohemo...
Autor principal: | Kuykendall, Andrew T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113291/ https://www.ncbi.nlm.nih.gov/pubmed/36944847 http://dx.doi.org/10.1007/s00277-023-05172-y |
Ejemplares similares
-
Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023) -
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020) -
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
por: Alvarez‐Larrán, Alberto, et al.
Publicado: (2022) -
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023) -
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)